Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107, for treating cognitive disorders Read more
Suven announces randomisation of first patient in Phase-2 POC clinical trial of Ropanicant (SUVN-911) Read more
Suven Pharmaceuticals financial results – strong show in FY20; outlook upbeat: ICICI Securities Read more
First patient randomised in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 Read more
